NT-501 implant

BIOLOGICAL2 trials

Sponsors

Neurotech Pharmaceuticals

Conditions

Idiopathic Juxtafoveal TelangiectasiaMacular Telangiectasia Type 2

Phase 1

Ciliary Neurotrophic Factor (CNTF) Safety Trial in Patients With Macular Telangiectasia (Mactel)

CompletedNCT01327911

Neurotech PharmaceuticalsIdiopathic Juxtafoveal Telangiectasia

Start: 2011-05-31End: 2016-09-30Updated: 2016-11-22

Phase 2

A Phase 2 Multicenter Randomized Clinical Trial of CNTF for MacTel

CompletedNCT01949324

Neurotech PharmaceuticalsMacular Telangiectasia Type 2

Start: 2014-04-30End: 2017-05-22Updated: 2018-09-12

Related Papers

Functional Relevance of Hyper-Reflectivity in Macular Telangiectasia Type 2.

2021-03-016 citations

Deep learning-based classification and segmentation of retinal cavitations on optical coherence tomography images of macular telangiectasia type 2

British Journal of Ophthalmology2020-11-2315 citations

Beyond Performance Metrics: Automatic Deep Learning Retinal OCT Analysis Reproduces Clinical Trial Outcome.

2019-12-2328 citations